Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $589,750.00 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPHGet Free Report) Director Michael A. Zasloff sold 12,500 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the sale, the director now directly owns 21,326 shares in the company, valued at approximately $1,006,160.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Amphastar Pharmaceuticals Stock Down 2.3 %

Shares of NASDAQ AMPH opened at $45.67 on Friday. The firm has a market cap of $2.20 billion, a price-to-earnings ratio of 17.70, a PEG ratio of 1.09 and a beta of 0.85. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. Amphastar Pharmaceuticals, Inc. has a 52-week low of $35.17 and a 52-week high of $67.66. The business’s 50 day moving average is $54.18 and its two-hundred day moving average is $52.61.

Institutional Trading of Amphastar Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMPH. Envestnet Asset Management Inc. purchased a new stake in Amphastar Pharmaceuticals in the first quarter valued at approximately $238,000. Raymond James & Associates purchased a new stake in shares of Amphastar Pharmaceuticals during the first quarter worth $599,000. Bank of New York Mellon Corp increased its position in shares of Amphastar Pharmaceuticals by 8.2% during the first quarter. Bank of New York Mellon Corp now owns 401,405 shares of the company’s stock worth $14,409,000 after acquiring an additional 30,462 shares during the period. Citigroup Inc. increased its position in shares of Amphastar Pharmaceuticals by 27.0% during the first quarter. Citigroup Inc. now owns 38,664 shares of the company’s stock worth $1,388,000 after acquiring an additional 8,224 shares during the period. Finally, Bank of Montreal Can increased its position in shares of Amphastar Pharmaceuticals by 2.9% during the first quarter. Bank of Montreal Can now owns 13,029 shares of the company’s stock worth $477,000 after acquiring an additional 371 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday. They set an “overweight” rating and a $60.00 price target on the stock. Finally, Bank of America assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 17th. They set a “neutral” rating and a $63.00 price target on the stock.

Read Our Latest Report on Amphastar Pharmaceuticals

About Amphastar Pharmaceuticals

(Get Free Report)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).

Read More

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.